PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Inclusion Criteria:

* Histologically or cytologically confirmed solid tumor or lymphoma that is refractory to standard therapy or for which no standard therapy exists
* No active, untreated, or symptomatic brain metastases

  * Patients with treated brain metastases are eligible provided metastasis are stable and the patient is off all steroids and anticonvulsants
* ECOG performance status 0-2
* Life expectancy ≥ 12 weeks
* WBC ≥ 3,000/mm\^3
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Bilirubin ≤ 1.5 mg/dL
* AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN in the presence of liver metastases)
* Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to PXD101, bortezomib, boron, or mannitol
* No peripheral neuropathy \> grade 1
* No uncontrolled intercurrent illness, including, but not limited to, any of the following:

  * Ongoing or active infection
  * Symptomatic congestive heart failure
  * Psychiatric illness or social situation that would preclude study requirements
* No significant cardiovascular disease, including any of the following:

  * Myocardial infarction within the past 6 months
  * New York Heart Association class III-IV heart failure
  * Unstable angina pectoris
  * Uncontrolled hypertension
  * Condition requiring antiarrhythmic therapy
  * Ischemic or severe valvular heart disease
  * Acute ischemia or active conduction system abnormalities by ECG
* No marked baseline prolongation of QT/QTc interval (repeated demonstration of a QTc interval \> 500 msec), long QT syndrome, or required use of concurrent medication during PXD101 administration that may cause torsade de pointes
* No severe medical or psychiatric problems of that would preclude study compliance
* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, carmustine, or mitomycin C)
* At least 4 weeks since prior radiotherapy and recovered
* At least 2 weeks since prior palliative radiotherapy to sites involving \< 35% of bone marrow reserve
* At least 4 weeks since prior investigational agents
* At least 2 weeks since prior valproic acid or any other histone deacetylase inhibitor
* No prior stem cell or bone marrow transplantation
* No concurrent radiotherapy or immunotherapy
* No concurrent hormonal therapy

  * Luteinizing hormone-releasing hormone agonists, selective estrogen receptor modulators, or aromatase inhibitors as chronic maintenance therapy allowed
* No concurrent combination antiretroviral therapy for HIV-positive patients
* No other concurrent investigational agents
* No other concurrent anticancer agents or therapies